PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.21%
EBIT growth of 47.21% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
40.44%
Operating income growth of 40.44% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
42.50%
Net income growth of 42.50% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
40.54%
EPS growth of 40.54% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
40.54%
Diluted EPS growth of 40.54% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
0.40%
Share change of 0.40% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
0.40%
Diluted share change of 0.40% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
51.97%
OCF growth of 51.97% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
51.97%
FCF growth of 51.97% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
95.95%
OCF/share CAGR exceeding 1.5x Healthcare median of 11.27% over 10 years. Joel Greenblatt would verify if a unique competitive moat underlies these cash flows.
79.78%
5Y OCF/share growth exceeding 1.5x Healthcare median of 18.61%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
21.40%
3Y OCF/share growth 1.25-1.5x Healthcare median. Mohnish Pabrai would confirm if cost advantage or brand strength explains near-term outperformance.
95.64%
Net income/share CAGR exceeding 1.5x Healthcare median of 37.30% over a decade. Joel Greenblatt might see a standout compounder of earnings.
74.54%
5Y net income/share CAGR > 1.5x Healthcare median of 29.02%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
42.66%
3Y net income/share CAGR 1.25-1.5x Healthcare median. Mohnish Pabrai would confirm expansions or margin boosts drive the short-term advantage.
160.55%
Equity/share CAGR exceeding 1.5x Healthcare median of 28.19% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
2.24%
Below 50% of Healthcare median. Jim Chanos suspects weak profitability or questionable capital allocation limiting equity growth.
-69.25%
Negative 3Y equity/share growth while Healthcare median is -19.95%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts or stagnation while Healthcare median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-14.61%
Negative BV/share change while Healthcare median is -0.42%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-8.07%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-50.78%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-4.70%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.